REG-Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
Key Highlights
- ➤Oculis (OCS) joins National MS Society’s five-year Campaign to End MS as Vision industry partner
- ➤Privosegtor PIONEER program includes two registrational trials in optic neuritis
- ➤Oculis targets fourth-quarter IND submission for Privosegtor in acute MS relapses
- ➤Oculis received positive FDA pre-IND feedback supporting Privosegtor’s acute MS relapse strategy
Expert Statements
Riad Sherif, M.D., Chief Executive Officer of Oculis
“Our sponsorship of the National MS Society's Campaign to End MS marks the beginning of what we believe will be a long-term partnership with an organization that has spent 80 years advancing research and care for people living with MS. We share the Society's commitment to accelerating progress for people affected by MS and, through our Privosegtor development program, we are working to advance a much-needed neuroprotective treatment option for patients experiencing optic neuritis and acute MS relapses.”
Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life
ZUG, Switzerland, October 1, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, is partnering with the National Multiple Sclerosis Society on its Campaign to End MS, as the industry partner focusing on Vision, officially launching today, on October 1, 2026. This 5-year campaign aims to accelerate research breakthroughs, improve access to care, and create a future where no one lives with the uncertainty of multiple sclerosis (MS). By bringing together people affected by MS, researchers, healthcare leaders, advocates, and supporters, the campaign seeks to translate scientific progress into meaningful advances in treatment and care, while strengthening the resources and support available to the MS community. Oculis’ sponsorship reflects a shared commitment to advancing innovation, addressing unmet needs, and improving the lives of people affected by MS.
Get started
Create a free account to read the full story.